Key result
Quinidine demonstrated a plasma half-life of 7.8 hours and 87% oral bioavailability, with higher than predicted concentrations in heart failure patients suggesting impaired elimination.
Why the study?
What are the pharmacokinetic parameters of quinidine in patients with arrhythmias, and how are they affected by heart failure?
Observational (n=51)
What are the pharmacokinetic parameters of quinidine in patients with arrhythmias, and how are they affected by heart failure?
Quinidine elimination or volume of distribution may be impaired in patients with heart failure, leading to higher than predicted drug concentrations.
Answers are grounded in this paper and cite their sources.
May warrant quinidine level monitoring in heart failure; leaves open prospective validation of dosing adjustments.
The absorption and disposition of quinidine were measured in nine patients following single oral and intravenous dosing. A new specific chromatographic method was used to measure the drug in plasma and urine. After intravenous administration, the plasma half-life (t1/2beta) was 7.8+/-0.7 h, the volume of distribution (Vd) was 3.0+/-0.5 liters/kg, and the total body clearance was 4.8+/-0.8 ml/min/kg. After oral administration, 87+/-7% (mean+/-SEM) was available to the systemic circulation. Quinidine was removed primarily by hepatic metabolism, with the renal clearance averaging only 1.0+/-0.2 ml/min/kg. Mean quinidine concentrations were estimated in 42 patients on chronic therapy by averaging blood levels during a dosing interval. In patients without heart failure, these corresponded well to mean drug levels predicted from the pharmacokinetic parameters measured after a single intravenous dose, but in patients with heart failure, the values for mean quinidine concentrations were higher than predicted. This suggests that impaired elimination of the drug or a decreased volume of its distribution, or both, may develop in heart failure.
No takes yet. Share an insight, caveat, or question.
Conrad et al. (1977) conducted an observational in Arrhythmias (n=51). Quinidine vs. Patients without heart failure was evaluated on Pharmacokinetic parameters (half-life, volume of distribution, clearance, bioavailability). Quinidine demonstrated a plasma half-life of 7.8 hours and 87% oral bioavailability, with higher than predicted concentrations in heart failure patients suggesting impaired elimination.
Synapse has enriched 10 related papers. Consider them for comparative context: